Aurlumyn (iloprost intravenous) / CiVi Biopharma - LARVOL DELTA

Iloprost (Aurlumyn) for frostbite. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Cardiovascular • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

COMPARISON OF THE ACUTE EFFECTS OF INTRAVENOUS ILOPROST ON FINGER POWER DOPPLER ULTRASOUND IN SCLERODERMA PATIENTS IN TWO INFUSION 4 WEEKS APART (EULAR 2024) - "PDUS examination of the PU and FP area can demonstrate an ILO chronic effect in SSc patients with long-lasting disease."

Clinical • Immunology • Rheumatology • Scleroderma • Systemic Sclerosis

SAFETY AND EFFICACY OF INTRAVENOUS ILOPROST IN THE TREATMENT AND PREVENTION OF SCLERODERMA-RELATED DIGITAL ULCERS (SSWC 2024) - "Our data shows that i.v. IIoprost has proved to be safe and effective for treating and preventing ulcers in scleroderma. The correlation between CV risk factors and the worsening of DUs underlines the importance of managing these conditions, not just in terms of prevention, but also as an integral part of the course of treatment for vasculopathy in scleroderma."

Clinical • Atherosclerosis • Cardiovascular • Diabetes • Dyslipidemia • Endocrine Disorders • Fibrosis • Immunology • Metabolic Disorders • Pain • Scleroderma • Systemic Sclerosis • CRP

ACUTE EFFECTS OF INTRAVENOUS ILOPROST ON FINGER POWER DOPPLER ULTRASOUND IN SCLERODERMA PATIENTS (SSWC 2024) - "PDUS examination of the PU and FP area can demonstrate an ILO acute effect in SSc patients with long- lasting disease. Therapy with CCB and presence of HAP impact on PD score improvement."

Clinical • Cardiovascular • Fibrosis • Hypertension • Immunology • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • Scleroderma • Systemic Sclerosis

Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 3) (clinicaltrials.gov) - P3; N=198; Completed; Sponsor: Eicos Sciences, Inc.; Active, not recruiting ➔ Completed

Clinical • Trial completion • Cardiovascular • Fibrosis • Immunology • Rheumatology • Scleroderma • Systemic Sclerosis

CiVi Biopharma to Participate in HC Wainwright BioConnect 2021 Conference (PRNewswire) - "CiVi Biopharma, Inc....today announces that Company management will participate in the upcoming HC Wainwright BioConnect 2021 Conference taking place virtually from January 11-14, 2021....'We enter 2021 in the final stages of a registrational Phase 3 clinical program in Systemic Sclerosis, an orphan indication for which there are no U.S. Food and Drug Administration approved treatments. Our goal is to complete enrollment and have topline data in mid-2021. In the interim, we continue to prepare our commercial launch strategy in the U.S.'"

P3 data: top line • Immunology • Systemic Sclerosis

Use of vasoactive/vasodilating drugs for systemic sclerosis (SSc)-related digital ulcers (DUs) in expert tertiary centres: results from the analysis of the observational real-life DeSScipher study. (PubMed, Clin Rheumatol) - "Our study shows that CCBs are still the most commonly used agents for DU management in SSc. The proportion of patients on combination therapy was low, even in patients with recurrent DU: almost one out of four patients with current and recurrent DU was on CCBs alone. Prospective analysis is planned to investigate the efficacy of different drugs/drug combinations on DU healing and prevention. Key Points • The analysis of DeSScipher, the first European multicentre study on management of SSc, has shown that the most commonly used vasoactive/vasodilating drugs for DU were CCBs, followed by intravenous Iloprost, ERAs and PDE-5 inhibitors. • More than half of the patients with recurrent DU received bosentan and/or sildenafil. • However, the proportion of patients on combination therapy of more than one vasoactive/vasodilating drug was low and almost one out of four patients with current and recurrent DU was on CCBs alone."

Clinical • Journal • Fibrosis • Scleroderma • Systemic Sclerosis

[VIRTUAL] Long-Term Tolerability of Aminaphtone in Raynaud's Phenomenon Secondary to Systemic Sclerosis (ACR-ARHP 2020) - "They were taking various concomitant treatments, including aspirin, calcium-channel blockers, cyclic intravenous iloprost, immunomodulators, endothelin receptor antagonists. Aminaphtone shows an acceptable long-term tolerability along with sustained efficacy in the management of SSc-related RP, without disabling side effects. A randomized controlled trial for Aminaphtone use in the management of SSc-related RP is desirable"

Fibrosis • Immune Modulation • Immunology • Inflammation • Pain • Scleroderma • Systemic Sclerosis • EDN1

Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 3) (clinicaltrials.gov) - P3; N=180; Recruiting; Sponsor: Eicos Sciences, Inc.; Active, not recruiting ➔ Recruiting

Clinical • Enrollment open • Fibrosis • Immunology • Scleroderma • Systemic Sclerosis

Dissecting the cellular mechanism of prostacyclin analogue iloprost in reversing vascular dysfunction in scleroderma. (PubMed, Arthritis Rheumatol) - "Our data suggests that the long-lasting effects of iloprost reflect its ability to stabilize adherens junctions, resulting in increased tubulogenesis and barrier function, and reduced Endo-MT. These results provide a mechanistic basis for the use of iloprost in treating SSc patients with RP and DU."

Journal • Fibrosis • Immunology • Scleroderma • Systemic Sclerosis • CDH5

CiVi Biopharma Resumes AURORA Phase 3 Clinical Trial of CIVI030 to Treat Systemic Sclerosis (PRNewswire) - "In people with SSc, digital ischemic episodes (RP) are often excruciatingly painful and associated with varying symptoms of pain, numbness, tingling, and discomfort. This causes significant disability and impacts quality-of-life and day-to-day functioning and may be the initial sign of long-term progressive complications due to inflammation and scarring of the vessels that supply blood to the digits,' said Dinesh Khanna, M.D..."

Media quote • Trial status • Systemic Sclerosis